Last updated on June 2018

Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-small Cell Lung Cancer (MK-3475-598/KEYNOTE-598)


Brief description of study

The purpose of this study is to determine the efficacy of pembrolizumab given in combination with either ipilimumab or placebo as first-line treatment in participants with metastatic non-small cell lung cancer (NSCLC). The primary hypothesis of this study is that overall survival (OS) and/or progression-free survival (PFS) is prolonged in participants who receive pembrolizumab and ipilimumab compared to those who receive pembrolizumab and placebo.

Clinical Study Identifier: NCT03302234

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Texas Oncology-Flower Mound ( Site 8007)
Flower Mound, TX United States
2.09miles
  Connect »